Buscar
Mostrando ítems 1-10 de 60
Fulvestrant más inhibidor CDK 4/6 para el tratamiento de cáncer de mama metastásico con receptores hormonales positivos / HER2 negativo
(Instituto Nacional de Salud, 2020-06)
El objetivo de la ETS rápida fue describir la evidencia científica disponible sobre el uso de fulvestrant + iCDK4/6 para el tratamiento del cáncer de mama HR+/HER2- metastásico
Fulvestrant más inhibidor CDK 4/6 para el tratamiento de cáncer de mama metastásico con receptores hormonales positivos / HER2 negativo
(Instituto Nacional de Salud, 2020-06)
El objetivo de la ETS rápida fue describir la evidencia científica disponible sobre el uso de fulvestrant + iCDK4/6 para el tratamiento del cáncer de mama HR+/HER2- metastásico
The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor
(Elsevier Ireland, 2015-11)
Fulvestrant, a selective estrogen receptor down-regulator (SERD) is a pure competitive antagonist of estrogen receptor alpha (ERα). Fulvestrant binds ERα and reduces the receptor's half-life by increasing protein turnover, ...
Fulvestrant treatment alters MDM2 protein turnover and sensitivity of human breast carcinoma cells to chemotherapeutic drugs
(Elsevier Ireland, 2014-08)
The human homologue of mouse double minute 2 (MDM2) is overexpressed in tumors and contributes to tumorigenesis through inhibition of p53 activity. We investigated the effect of the anti-estrogen fulvestrant on MDM2 ...
Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma
(Kluwer Academic/plenum Publ, 2003-05)
The purpose of this study was to evaluate the effect of the selective estrogen receptor modulators raloxifene and tamoxifen and of the pure antiestrogen fulvestrant on tumor growth and progesterone receptor (PR) expression ...
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study
(SPRINGERNEW YORK, 2012)
NEWEST (Neoadjuvant Endocrine Therapy for Women with Estrogen-Sensitive Tumors) is the first study to compare biological and clinical activity of fulvestrant 500 versus 250 mg in the neoadjuvant breast cancer setting. We ...
Fatty acid synthase is a key enabler for endocrine resistance in heregulin-overexpressing luminal b-like breast cancer
(MDPI AG, 2020-10)
HER2 transactivation by the HER3 ligand heregulin (HRG) promotes an endocrine-resistant phenotype in the estrogen receptor-positive (ER+) luminal-B subtype of breast cancer. The underlying biological mechanisms that link ...
Effects of the oestrogen receptor antagonist Fulvestrant on expression of genes that affect organization of the epididymal epithelium
(Wiley-Blackwell, 2014-07-01)
The role of oestrogens in epididymal function is still unclear. Knockout of the oestrogen receptor ESR1 (Esr1-/-) or treatment with the anti-oestrogen Fulvestrant affect epididymal milieu and sperm motility. We investigated ...